Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $16

Benzinga · 2d ago
Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.